MULTIMODALITY AND MULTIPARAMETRIC IMAGING
IN ADVANCING HEALTHCARE
TOWARDS PERSONALIZED MEDICINE ______________________________________________________________________
Following the previously conducted symposia on dedicated medical imaging instrumentation we are presently organizing the 5th workshop of this exclusive series to be held in the East of the beautiful island of Sardinia.
The purpose of this meeting is to discuss the role of the multimodality and multi-parametric imaging modalities on the vision of individualized/personalized medicine.
Based on the breakthroughs in genomic, proteomic and metabolic profiling Precision Medicine has emerged as a novel health-care paradigm. Precision Medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. It involves integrating information from multiple sources to achieve a precise diagnosis, personalized target treatment, and adequate response assessment.
The “-omics” analysis as well as histopathology are important input parameters for a precise diagnosis, however, as they rely on small biopsy samples or body fluids, they do usually not map the entire profile of the disease. Tumors typically have a spatially and temporally varying molecular and genetic profile; the same applies to neurodegenerative, cardiovascular or autoimmune diseases. Therefore, “liquid diagnostic parameters” can provide only a snapshot of the entire disease while Multiparametric Imaging can holistically map molecular, functional and habitant varieties of the same or multiple diseases.
Thus, Multiparametric Imaging and Imaging-Guided Interventions, which provide multiparametric information and enable focused, minimally invasive treatments, are key elements of complex Precision Diagnosis and Personalized Medicine. Different diagnostic approaches utilizing bioinformatics, machine learning, and systems biology will be used to mine the essential information and fuse the precise but spatially and temporally restricted disease characterization of “-omics” and histopathology with the holistic data of Multiparametric Imaging. The emerging fields of Radiomics and Radiogenomics are linking genotypic information to phenotypic disease manifestations from imaging. Because of the growing volume and complexity of imaging data and its necessary linkage to metadata, decision-support algorithms will be required to help physicians applying the most essential patient data for optimal management.
Based on the above emerging realities the MEDAMI Forum series of events is trying to define the role of and needs for Multiparametric Imaging in the development of healthcare towards Personalized/Precision Medicine and to determine the impact of those developments on collaboration- and business models in the future.
What are the key questions the MEDAMI 2017 will address?
Personalized Medicine – what will be the impact of what? on current medical imaging and image guided interventions? Is there a need for organ specific (precision) medical imaging?
Which medical areas have the the strongest impact/needs?
Are there new imaging technologies and methods for precision imaging?
In which areas are new biomarkers and imaging agents needed? What shall be the role of such new tracers and imaging agents in personalized medical imaging?
What funding mechanisms can be employed for the development of imagers and imaging agents that finally lead to widespread clinical application? What are the roles of funding agencies and industry?
How does Personalized Medicine impact the business models of stakeholders (industries, clinics, health care providers)?
The program of the MEDAMI 2017 is being developed . A number of Key Opinion Leaders (KOL’s) from Biology, Medicine and Technology fields have already been contacted to give lectures.
The program of the forum primarily will consist of invited talks by key opinion leaders and experts from around the world. However, a limited number of abstracts for oral or poster presentations will be accepted. If you have to report on a topic that you think fits into the scope of the program we will be happy to receive your abstract.
Preliminary list of key speakers who accepted to come and talk:
- Prof. Roderic Pettigrew, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)- USA
- Prof. David Townsend, National University of Singapore, inventor of PET/CT
- Prof. Craig Levin, Stanford Molecular Imaging Instrumentation Laboratory (MIIL) – USA
- Prof. Bernd Pichler, University of Tubingen (Germany)
The meeting format fosters a close interaction between different stakeholders from academia, medical institutions and organizations, regulatory agencies and industry.
Nicolas Petrick (Center for Devices and Radiological Health (CDRH), Food and Drug Administration (FDA)) - FDA perspective on the role of FDA in the emerging field of precision medicine medical imaging
Bernd Stowasser (Sanofi-Aventis, on behalf of the European Federation of Pharmaceutical Industries and Associations (EFPIA)) - Academic-Industry partnership: Can the IMI PPP model be extended/exported to medical imaging industry?
Session 1.2: Research concepts/activities (Moderator: York Haemisch)
Piotr Maniawski (Philips Healthcare, on behalf of the Association of Imaging Producers and Equipment Suppliers (AIPES)) - The AIPES organization and its role in supporting medical imaging development
Marco Paganoni (Univ. of Milano) - ERAMIT
Maurizio Conti (Siemens Healthineers, Knoxville) - Challenges and trends in molecular imaging, an industry research viewpoint. The role of radiotracers in modern diagnosis and expensive/advanced therapies
Session 1.3: Diagnostic Imaging, theranostics and the -omics (Moderators: Bernd Pichler, Jonathan Disselhorst)
David Townsend (National University of Singapore) - PET/CT, PET/MR and Precision Medicine: some alternative facts
Bernd Pichler (Dept. of Pre-clinical imaging and Radiopharmacy University of Tuebingen) - Combining multiparametric imaging data with –omics information for precision medicine
Constantin Lapa (Nuclear Medicine, University of Wurzburg) - Theranostics and multimodality imaging
Session 1.3 (cont)
Jonathan A. Disselhorst (University Tuebingen) - Imaging Tumor Heterogeneity
P. Pevsner - How cost-effectiveness of a diagnostic medical imaging procedure is determined
Roderic Pettigrew (Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)) - Multimodality/Multiparametric Imaging and Precision Medicine
ROUND TABLE - The relation of academia and industry in the development of medical and molecular imaging technologies. Chair: Paul. Lecoq, CERN - Representatives of funding institutions, industries, MDs, physicists/technologists Outcome: proposals for improvement of academia-industry relation
Session 2.1: Neurodegenerative diseases and brain disorders
Charles R.G. Guttman (Center for Neurological Imaging, Harvard Medical School) - Neurodegenerative diseases - an overview
Valentina Garibotto (Univ.of Geneva) - Multimodal/multiparamenter imaging – main modalities and applications: link to biomarkers and personalized medicine
Martin Walter (University of Tuebingen, Germany) -Multimodal imaging in psychiatry
Vesna Sossi (University of British Columbia) - PET/MRI imaging in neurodegeneration: novel metrics for early disease detection and effect of therapy assessment
Session 2.2: Brain biomarkers and brain imaging initiatives
Christer Halldin (Karolinska Institutet, Stockholm) - PET Radioligands for Neuroscience and Drug Development
Ilan Rabiner (Chief Medical Officer, Head of Imaging Applications, Imanova Ltd., UK) - Building the Three Pillars- Imaging in early phase drug development
Paul M. Matthews (Head of Brain Imaging Sciences, Imperial College, London) - Challenges and opportunities for brain imaging with large population datasets
Simone Sarasso (Dept. of Biomedical Sciences, University of Milano) - Major brain initiatives
Session 2.3: Brain imaging - new technologies
Stan Majewski (University of Virginia) - Dedicated PET brain imaging devices
Bernd Pichler (Director, Dept. of Pre-clinical imaging and Radiopharmacy, University of Tuebingen) - Developments in MRI, MEG and EEG
Session 2.3: Brain imaging - new technologies
Jose Maria Benlloch (Institute of Molecular Imaging, University of Valencia) - Mindview: multimodal imaging of neurological disorders
Alberto del Guerra (Department of Physics, University of Pisa) - A trimodality (EEG/MR/PET) scanner for brain imaging
ROUND TABLE - Molecular imaging and -omics: competition or complementarity for Precision medicine? Chair: Vesna Sossi, UBC, Vancouver Representatives of funding institutions, industries, MDs, physicists/technologists